Showing results (11-20 of 18) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent p300/CBP InhibitorAnthony Mastracchio, Chunqiu Lai, Enrico Digiammarino, et al.Bioorganic & Medicinal Chemistry Letters|May 3, 2006
Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-alkyl-4-hydroxyquinolon-3-yl-benzothiadiazine sulfamidesA Chris Krueger, Darold L Madigan, Wen W Jiang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumorsJoann P Palma, Yi-Chun Wang, Luis E Rodriguez, et al.Bioorganic & Medicinal Chemistry Letters|February 15, 2011
Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moietyDouglas K Hutchinson, Charles A Flentge, Pamela L Donner, et al.Journal of the American College of Cardiology|February 25, 2014
Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trialKenneth W Mahaffey, Claes Held, Daniel M Wojdyla, et al.Journal of Medicinal Chemistry|October 1, 2024
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In Vivo Target EngagementRobin R Frey, Navendu Jana, Jacob V Gorman, et al.Nature|September 28, 2017
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.Nature|May 18, 2018
Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumoursLoren M Lasko, Clarissa G Jakob, Rohinton P Edalji, et al.Pageof 2